Esperion Therapeutics (NASDAQ: ESPR) reported Q2 EPS of ($0.02), $0.12 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $82.39 million versus the consensus estimate of $63.54 million.

For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.